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METHODOLOGY
Realising stratified psychiatry using 
multidimensional signatures and trajectories
Dan W. Joyce1*, Angie A. Kehagia2, Derek  K. Tracy1, Jessica Proctor1 and Sukhwinder S. Shergill1
Abstract 
Background: Stratified or personalised medicine targets treatments for groups of individuals with a disorder based 
on individual heterogeneity and shared factors that influence the likelihood of response. Psychiatry has traditionally 
defined diagnoses by constellations of co-occurring signs and symptoms that are assigned a categorical label (e.g. 
schizophrenia). Trial methodology in psychiatry has evaluated interventions targeted at these categorical entities, 
with diagnoses being equated to disorders. Recent insights into both the nosology and neurobiology of psychiatric 
disorder reveal that traditional categorical diagnoses cannot be equated with disorders. We argue that current quan-
titative methodology (1) inherits these categorical assumptions, (2) allows only for the discovery of average treatment 
response, (3) relies on composite outcome measures and (4) sacrifices valuable predictive information for stratified 
and personalised treatment in psychiatry.
Methods and findings: To achieve a truly ‘stratified psychiatry’ we propose and then operationalise two necessary 
steps: first, a formal multi-dimensional representation of disorder definition and clinical state, and second, the similar 
redefinition of outcomes as multidimensional constructs that can expose within- and between-patient differences in 
response. We use the categorical diagnosis of schizophrenia—conceptualised as a label for heterogeneous disor-
ders—as a means of introducing operational definitions of stratified psychiatry using principles from multivariate 
analysis. We demonstrate this framework by application to the Clinical Antipsychotic Trials of Intervention Effective-
ness dataset, showing heterogeneity in both patient clinical states and their trajectories after treatment that are lost in 
the traditional categorical approach with composite outcomes. We then systematically review a decade of registered 
clinical trials for cognitive deficits in schizophrenia highlighting existing assumptions of categorical diagnoses and 
aggregate outcomes while identifying a small number of trials that could be reanalysed using our proposal.
Conclusion: We describe quantitative methods for the development of a multi-dimensional model of clinical state, 
disorders and trajectories which practically realises stratified psychiatry. We highlight the potential for recovering 
existing trial data, the implications for stratified psychiatry in trial design and clinical treatment and finally, describe 
different kinds of probabilistic reasoning tools necessary to implement stratification.
Keywords: Stratified psychiatry, Trials, Methodology, Multivariate
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Background
There is a growing consensus that psychiatric disorders—
defined as syndromes in categorical diagnostic systems 
such as the International Classification of Diseases [1] 
and the Diagnostic and Statistical Manual [2]—are het-
erogeneous in terms of aetiology, presenting psycho-
pathology, and treatment response. Simultaneously, it 
is now recognized that the search for the aetiology and 
treatment of psychiatric disorders is not well-served 
when traditional categorical definitions of syndromes 
in the ICD-10 and DSM-5 are effectively equated with 
disorders. Instead, the emerging paradigm of stratified 
psychiatry [3] emphasises multifactorial predictors or 
moderators of disorders grounded in underlying neuro-
biology, gene/environment interactions and intermediate 
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endophenotypes such that the final phenotypic expres-
sion does not necessarily align with the “classical” disor-
der specifications of e.g. schizophrenia, bipolar affective 
disorder and mood disorders.
This has led to the development of the Research Domain 
operational Criteria (RDoC) [3–8] and the roadmap for 
mental health research (ROAMER) [9]. These proposals 
reconstruct psychiatric disorders on the basis of biologi-
cal mechanism and endophenotypes that describe (1) the 
aetiology of the disorder, (2) help identify predictors and 
biomarkers for the disease and/or sub-type the disease 
and (3) variation in response to treatment. This may help 
resolve the apparent dilemma experienced in everyday 
clinical practice, where two patients respond differently 
to the same intervention—one patient’s symptoms and 
signs improve substantially but another’s remain stub-
bornly unresponsive. Through the lens of stratified psy-
chiatry, these two patients share some features, but may 
not necessarily have the same disorder despite a common 
categorical label of, for example, schizophrenia.
Recent studies examining illness features of mood dis-
orders have shown that combinations of clinical vari-
ables predict response to selective serotonin reuptake 
inhibitors (SSRIs) [10–12]. In substance misuse disor-
ders, cocaine dependence is predicted by a combination 
of parameters in neurocognitive measures of impulse-
control [13]. In schizophrenia, antipsychotic treatment 
response and pathogenesis are predicted by overlapping 
sets of genes [14].
To constrain our scope, we necessarily focus on the sin-
gle group of schizophreniform disorders. The proposals 
that follow are, however, equally applicable to other psy-
chiatric disorders but the grouping of phenotypes will 
differ. For example, in terms of the DSM5, depressive dis-
orders may be too coarse-grained, but persistent depres-
sive disorder (dysthymia) and major depressive disorder 
may be appropriate because they share syndromic fea-
tures. However, depressive episodes with psychotic or 
catatonic features might be better dealt with separately 
because of the qualitatively different presentation of 
these patients.
Given our scope, and to make our examples concrete, 
we further focus on the neurocognitive symptoms of psy-
chotic disorders that are clinically significant for progno-
sis and quality of life [15, 16] and have proven notoriously 
difficult to treat with either cognitive or pharmacologi-
cal interventions, despite over a decade of clinical trials. 
Beyond the obvious explanation that some of the com-
pounds or interventions trialled do not affect the relevant 
neurophysiological substrates of these features of the ill-
ness, we propose that the failure stems from methodo-
logical problems inherited from broader considerations 
about disorder definition and the nature of treatment 
response in individuals recruited into these trials.
To proceed, we first consider how disorder definition 
can be reconceptualised using clinical signatures and a 
multi-dimensional understanding of signs and symp-
toms of illness which serves recruitment of patients 
into studies, in other words, patient stratification. Clini-
cal signatures represent an individual’s disease state at a 
given time, defined along different quantified dimensions 
(loosely, ‘axes’ in a multidimensional space) of symp-
toms, signs or quantitative/qualitative measures (such 
as the individual’s loading or expression for a biomarker) 
that we define and operationalise from first principles 
using concepts found in multivariate statistics and pat-
tern recognition. In the context of both clinical trials and 
interventions more generally, response is then naturally 
defined as a trajectory between clinical signatures before 
and after interventions for the same patient. In con-
trast, in the traditional analysis of trial data, response is 
defined a priori as an aggregate univariate outcome for a 
group of patients defined by their shared categorical dis-
order. We propose that with the richer multidimensional 
information contained in signatures, treatment response 
can be framed as modelling trajectories, retaining valu-
able information that predicts or stratifies how individual 
patients might respond. We then show how this pro-
posal can be made compatible with traditional analyses 
by defining outcomes as a function of trajectories, rather 
than starting with univariate aggregate outcomes.
These principles are then applied in the context of a 
systematic review of a decade of trials in the treatment of 
neurocognitive features of schizophreniform disorders, 
evaluating their suitability or “readiness” for a stratified 
approach. We conclude with proposals for the future 
design and analysis of patient-level data for trials and 
clinical practice.
Step one: multidimensional definition of disorder
Moving beyond categorical diagnoses
In psychiatry, disorders have historically been defined by 
necessity as syndromes with operationalised thresholds 
for symptoms and signs to justify a categorical diagno-
sis. Modern classification systems such as ICD and DSM 
follow from the traditions of nineteenth century medi-
cine [17]. Psychiatric disorders appear as categories in 
the ICD system from version 6, published in 1948 [18] 
with the first edition of the DSM arriving in 1952. The 
empirical field-trialled approach to definitions reflected 
in DSM-III (1980) resulted in operational criteria, which 
are reflected, though less prescriptively, in ICD from 
version 9 (in use from 1979 to 1994). The development 
of the ICD follows its origins as a statistical method for 
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indexing causes of mortality and morbidity [18] whereas 
the DSM-IV and later, DSM-V, continue to focus on 
operational criteria for making diagnoses. The ICD in 
its current revision (version 10) continues to be hierar-
chical, whereas the DSM-V is more dimensional and 
organised around current understanding of phenotypes. 
Because of it’s operational, criteria-based approach, the 
DSM is often used for clinical and research work while 
outside Europe, the ICD10 is used primarily as a hospi-
tal and healthcare-provider coding system, rather than 
a diagnostic system per se. In either case, clinicians use 
categorical diagnoses as a technical shorthand, to provide 
treatments to patients who fit the syndromic description 
(i.e. given by the DSM criteria or described by the ICD 
narrative) and who are presumed to have the nominal 
disorder (e.g. schizophrenia, major depressive disorder). 
Medications are given regulatory approval if they can be 
shown to treat the categorical disorder [19, 20], on the 
basis of clinical trials, in which patients are assigned to 
treatment based on the same categorical disorders. We 
will argue that this fails patients given our contemporary 
understanding of the aetiology of psychiatric disorders, 
how we design trials and decide on outcomes.
In the mid-twentieth century, advances in psychophys-
ics, neuroscience and the emergence of an overarching 
cognitive science reframed observable behaviour in the 
context of its proximal causes i.e. in broadly descending 
levels of abstraction as cognitive, neurophysiological, 
molecular and genetic systems. Within a classification 
system, the definition of categorical diagnoses is enforced 
by mutual exclusivity such that these categorical labels 
represent a ‘disorder’ [21] and the assignment of more 
than one of these represents comorbidity. Clinical man-
agement is then necessarily ‘mapped’ onto these catego-
ries [22] to produce clinical guidelines for treatment. This 
applies even when multi-axial versions of classification 
systems are considered.
However, equating disorders to their syndromes is 
demonstrably artificial. In the past decade, research on 
schizophrenia has benefitted from insights into genetics 
of specific features of the disorder; for example, variation 
in DTNBP1 with severity of general cognitive perfor-
mance [23], polymorphism of the COMT gene in work-
ing memory [24, 25] and executive function that are 
further implicated in response to antipsychotic medica-
tion [24, 26, 27]. Similarly, genomic studies [28, 29] and 
phenotype clustering [28, 30–32] have shown that the 
traditional view of diagnostic categories has less utility 
than symptom- and sign-specific definition of disorder 
and illness at the individual level.
Moreover, categorical classification cannot readily 
accommodate the observation of shared symptoms in 
the face of divergence in neurodevelopment. Diagnostic 
categories may exhibit marked differences in neurode-
velopment [33–35] but also overlap in terms of shared 
symptoms: psychotic features are seen in borderline 
personality disorder [36–39], and bipolar disorder and 
schizophrenia both exhibit similarities in non-verbal 
communication [40], affective symptoms [41], cogni-
tive deficits [42, 43], genetic risk factors [44–46] and 
a broader trans-diagnostic ‘psychosis’ phenotype [47]. 
The observation that signs or symptoms are rarely exclu-
sive is an inevitable stumbling block for categorical 
classification in psychiatry, because they are a distinct 
manifestation of neurobiological dysfunction whose idi-
osyncratic expression in an individual patient is shaped 
by complex environmental factors in the history of that 
individual’s illness. Any given sign or symptom is likely 
shared across categorical disorder boundaries and is 
rarely observed in only a single disorder. Therefore, psy-
chiatric disorders as entities can only be investigated if 
signs and symptoms are considered as arising in “bot-
tom up” fashion from dysfunction in neurophysiology, 
genetics and environment—a principle embodied in both 
RDoC and ROAMER. The implication for patients is then 
apparent: the unique cluster of signs and symptoms, their 
disorder signature, may arise from a number of interact-
ing dysfunctional cognitive systems that further map to 
a number of underlying neurobiological deficits. Thus, in 
a group of patients, the meaningful observable variables 
are the state of their signature components rather than 
their a priori diagnoses according to a categorical system.
Dimensional definitions of disorder
In recent years, dimensional definitions of disorders have 
been advocated [41, 48–50] such that disease differentia-
tion, between health and pathology as well as between 
different disorders with some shared symptoms and signs 
[50], proceeds by comparing a given patient state (signa-
ture) to prototypes along one or more dimensions/scales. 
Some have noted that this approach is complicated by the 
absence of a “mathematical, precise resolution of what 
constitutes ‘sufficiently similar’ patients” [51], which in 
fact succinctly captures the focus of the current proposal, 
as it is central to and necessary for the concept of strati-
fied psychiatry [3].
Any proposal for a signature and prototype based 
approach needs to be capable of modelling differences and 
similarities between patients. For ease of exposition, but 
without loss of generality, consider Fig. 1a, where two per-
pendicular ‘axes’ form a plane (a two dimensional Cartesian 
space) with each axis representing a monotonically increas-
ing scale from low-to-high symptom ‘load’ (for example, 
in schizophreniform illness, the axes could represent psy-
chotic positive and negative symptom load respectively). 
A patient’s signature at a given time is defined as the point 
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on the plane given by its two-dimensional coordinates. Fig-
ure  1a shows two patients with very different signatures 
at time 1, but signatures at time 2 which are close in the 
plane. Under this model, the cause of these different signa-
tures and trajectories could represent (1) different interven-
tions, (2) different responses to the same intervention or (3) 
patients with different disorders (but with the same categor-
ical disorder label). We note that although we use symptoms 
as examples, these axes could as easily represent any quan-
titative state ‘marker’; for example, a genotypic risk-profile 
score [29], functional neuroimaging activation of cortical 
areas [52] or indices of neurocognitive performance [53].
When we populate the space of signatures with multi-
ple patients, clustering of individuals in certain locations 
may be observed. Figure  1b expands on this showing 
a two dimensional example of the positive and nega-
tive symptoms scores of 100 simulated patients. The 
patients’ signatures are shown as two tentative clusters 
(black and grey points). Patients’ similarity to each other 
(illustrated as dotted lines) is inversely proportional to 
the Euclidean (‘straight line’) distance between them. 
This intuition of defining signatures and spaces derives 
from the formal definition of Hilbert and inner-product 
spaces that generalise Cartesian co-ordinates [54, 55] 
such that ideas of similarity and distance can be naturally 
extended to describe arbitrarily high-dimensional spaces. 
Each dimension can be concretely envisaged as an axis 
orthogonal (perpendicular) to the others and represents 
any measurement of clinical state. It will later be demon-
strated how the 30-dimensional ‘space’ of signatures can 
be formed by translating the Positive and Negative Symp-
tom Scale (PANSS) items into patient signatures.
Operationalising signatures, prototypes and stratification
In Fig. 1b it can be seen that the two groups of patients 
have a prototype, shown as coloured diamonds that are 
the centroids (the multivariate statistical means, or first 
moments) of the two distributions and labelled Class A 
and B. Note that these prototypes need not represent 
categorical disorders in the ICD10/DSM5 sense, but, 
instead, meaningful groups of patients with sufficiently 
similar signatures. Stratification then becomes the task 
of assigning membership of a given patient (signature) to 
one of the two tentative groups (classes), where ‘member-
ship’ can be either a discrete or continuous property.
Stratification has been implemented traditionally by 
inclusion and exclusion criteria that attempt to control 
patient heterogeneity by defining the categorical diag-
nosis of interest, and then specifying confounds or dis-
ease features that would alter the interpretation of the 
trial results. The process of specifying these criteria to 
arrive at a prototypical patient suitable for a given trial 
may serve for diseases characterised by few and narrowly 
defined criteria and low comorbidity, which dictates by 
necessity low heterogeneity among the individuals that 
make up that population. This however, is not the case 
in psychiatry, psychosis being a prime example, which 
demonstrates high heterogeneity, evident in well docu-
mented differences in clinical presentation as well as 
drug response. Traditional approaches to trial design 
and statistical data treatment are not equipped to deal 
with heterogeneity (i.e. non-normality, outliers); they 
use inclusion/exclusion criteria to overcome it, in the 
process sacrificing valuable data from those non-proto-
typical individuals that fail at the cut-off, which leads to 
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Fig. 1 a Schematic representation of two patients’ signatures at time 1 (before intervention) and time 2 (after intervention) with connecting lines 
representing trajectory. b A space of patient signatures along dimensions of positive and negative symptoms, with black and grey points represent-
ing patients belonging to two tentative clusters of patients. Diamonds show the centroids (prototypes) of the two patient categories. Dotted lines 
represent between patient-signature similarity and solid lines represent class membership as proportional to the distance of a given patient to the 
nearest prototype/centroid. The blue solid line represents a linear discriminant separating the two classes such that the overall misclassification error 
is minimised, as might be estimated or learned by, for example, a support vector machine or linear discriminant analysis
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trial outcomes and drugs that work for some but not all. 
In “Experiment one: patient heterogeneity and stratifica-
tion” section, we illustrate how data-driven approaches 
are ideally suited to expose and capitalise on this het-
erogeneity, by taking into account the entire sample, and 
rather than binary inclusion/exclusion, treat each indi-
vidual on the basis of a similarity score to an estimated 
prototype. This approach maximises the utility of each 
patient enrolled in a trial, or registered on a database, 
flexibly adapting to subtly shifting prototypes which 
may vary between datasets and importantly, represents 
a powerful tool with which to use heterogeneity rather 
than seek to limit it.
In the discrete case, ‘hard-classifying’ to stratify 
patients involves assigning their signature to one of the 
mutually exclusive discrete classes (A or B) according to 
a decision rule; for example, in Fig. 1b, we compute the 
distance of any signature to the prototypes (centroids) of 
Class A and Class B, then assign the signature to the class 
with smallest distance. Alternatively, and especially rel-
evant to our proposal, is that membership to a class can 
be a continuous ‘soft’ property. In this case, assignment is 
probabilistic, i.e. a signature belongs to class A or B with 
probabilities 0.7 and 0.3 respectively, where the likeli-
hood of belonging to A or B is some function of the dis-
tance. Both hard and soft membership can be made more 
flexible by formulating the problem in Bayesian decision 
theory (see [56] Chapter  2 for a thorough treatment) 
where the probability of class membership for a given sig-
nature can be biased towards or away from prototypes by 
defining more sophisticated products of a likelihood (e.g. 
the distance measure in this example) and priors over 
classes (e.g. ‘weighting’ the class membership by preva-
lence of certain prototypes).
Learning models of signatures
Thus far, we have shown that multidimensional signa-
tures can form a space, how a metric can be defined that 
exposes similarity or difference between patients and 
the uses of these definitions for ‘hard’ and ‘soft’ stratifi-
cation. In any statistical model, relationships between 
variables are most often acquired, learned or estimated 
from the data. We consider two situations; first, a col-
lection of signatures, but no a priori information about 
their relationship and second, a set of signatures associ-
ated with other known variables. The first scenario rep-
resents a situation where we have signatures and seek a 
data-driven model by inferring prototypes supported by 
the data. For example, given a large number of patients 
whose PANSS scores (a 30-item instrument) are used 
to populate a 30-dimensional space, we might seek a 
set of prototypes that represent clusters of patients that 
are sufficiently similar such that stratified assignment 
to intervention occurs by similarity in psychopathol-
ogy. Of note, this represents exploration and discovery 
of candidate prototypes and the model is constructed 
by ‘unsupervised’ learning. In Fig.  1b, stratification of a 
new, previously unknown patient would be some func-
tion of the distance to discovered prototypes (solid green 
and red lines). This straightforward idea is commonplace 
in the literature on statistical pattern classification and 
machine learning—see [57] chapter 13 and 14. The sec-
ond scenario represents a different situation where we 
have existing information about the patients, for exam-
ple, where we have patient signatures before an inter-
vention and an indicator of change following treatment 
(note that we do not necessarily restrict ourselves to a 
dichotomised or even univariate definition of response or 
failure, as we will show later when we consider trajecto-
ries). In this case, using existing knowledge of treatment 
response can help validate an existing stratification pro-
tocol or to derive one informed by known outcomes (i.e. 
we know which patients responded, but not why given 
their signatures). Thus, the aim is to model the ‘mapping’ 
from patient signatures before intervention, to treat-
ment response after intervention. In this context, esti-
mating the model proceeds by ‘supervised’ learning and 
results in a discriminant function such as the solid blue 
line shown in Fig. 1b where in contrast to the unsuper-
vised case, assignment of signatures to class A and B was 
known in advance. Previously unseen patients are then 
prospectively stratified based on which ‘side’ of the dis-
criminant line they fall.
It is worth noting that these concepts of representa-
tion, similarity/distance and learning/model estimation 
have a long tradition in statistics, pattern recognition 
and machine learning, where they appear in the context 
of class assignment based on prototypes by learning vec-
tor quantisation and self-organising maps [58], binary or 
multinomial classification using linear and quadratic dis-
criminant analysis [59], generalised linear models such as 
logistic regression [60], support vector machines [61] and 
Gaussian process regression and classification [62].
There are important considerations in choosing any 
data-driven unsupervised clustering or supervised classi-
fication algorithm (when a priori assumptions about pro-
totypes exist). For unsupervised clustering methods, the 
choice of similarity metric between signatures as well as 
the measure of cluster optimality will dictate the discovered 
prototypes and need to be justified based on the data and 
their intended use. Rather than use a supervised approach 
reflecting a priori information about presumed prototypes, 
in Experiments 1 and 2, we use unsupervised clustering to 
allow the data to support candidate prototypes that reveal 
heterogeneity. The algorithm we chose [63] embodies the 
aforementioned similarity metric (see “Operationalising 
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signatures, prototypes and stratification” section) and 
implements an optimality measure based on a further 
measure that constrains the number of discovered proto-
types, such that a candidate prototype differentiates itself 
from others while binding together similar signatures.
There have been attempts to adopt multi-dimensional 
principles to the problem of (1) signature definition 
(2) treatment outcomes and (3) diagnostic prediction. 
However, none has applied a multidimensional defini-
tion consistently across all levels from disorder defini-
tion through to disease state and outcome. For example, 
while multivariate signatures based on symptomatology 
were used in studies predicting outcome for first-episode 
psychosis [64] and symptom severity and persistence in 
post-traumatic stress disorder (PTSD) [65], only univari-
ate and dichotomised outcomes were addressed and cat-
egorical diagnosis was presumed. When neuroimaging 
data were used as the signature, machine learning classi-
fiers were used to predict categorical diagnosis [66], tran-
sition from an at-risk state to a dichotomised ‘psychosis 
versus health’ outcome [67] and dichotomised clozapine 
response [68, 69], or univariate aggregate predicted uni-
variate global assessment of function (GAF) [70]. Only 
one study [71] used machine learning to predict multiple 
outcomes in major depressive disorder although again, 
these were dichotomised and did not model trajectories 
as multidimensional constructs. We argue that stratified 
psychiatry should avoid categorical diagnoses and uni-
variate treatment outcomes.
Step two: beyond univariate outcomes
Analyses of clinical trial data typically attempt to find a 
parsimonious group of independent variables to predict a 
univariate primary outcome, which is, most often, a con-
tinuous scalar variable representing aggregate scores on 
a clinical instrument or a dichotomised outcome based 
on a cut-off point applied to some aggregate score. For 
example, response to an intervention may be defined as 
at least 50% reduction in the overall/aggregated symp-
tom score. Ideally, there will be predictors that exhibit 
low collinearity, enabling independent effects on the 
outcome/dependent variable to be modelled using well 
understood statistical methods (e.g. logistic regression or 
survival analysis for dichotomised outcomes, and linear/
generalised linear models for continuous outcomes). The 
appeal is obvious—without some clear, univariate pri-
mary endpoint (dependent variable), there would appear 
to be no tractable way of analysing the data.
However, evidence-based treatment protocols derived 
from randomised controlled trials (RCT), including 
meta-analysed evidence and naturalistic effectiveness 
trials such as CATIE, do not translate reliably to clini-
cal practice [72] and leads to publication bias [73]. This 
is a direct consequence of categorical disorder definition: 
patients rarely conform to the strict inclusion/exclusion 
criteria of RCTs, they often exhibit comorbidity, in itself 
a consequence of categorical disorder definitions as their 
symptoms do not conform to the demarcated boundaries 
of their assumed categorical diagnosis [74] and finally, 
analysis emphasises average response in the presumed 
homogenous patient group with the same categori-
cal disorder. In recognition of this gap between the evi-
dence base and clinical practice, researchers have begun 
exploring individualised/stratified medicine. Recent 
translational research has focused on biomarkers [75] 
and signatures [76, 77], where multi-dimensional clini-
cal metrics can be used to define trajectory of illness [78], 
response to treatment and relapse [79]. In other words, 
multivariate outcomes derived from multidimensional 
signatures and their trajectories.
This problem of average response is shared with pain 
medicine, where the classification of pain syndromes is 
a function of diffuse patho-physiological mechanisms 
(which are also difficult to measure ‘objectively’) and 
individual response to pain medications varies substan-
tially also as a function of psychological and social fac-
tors. A study of 200 fibromyalgia patients described 
treatment response to pregabalin 450 mg for 14 weeks as 
a bimodal distribution [80]. Given the categorical diagno-
sis of fibromyalgia, the notion of average response pro-
vides no useful estimate of the effect of the drug because 
patients tended to either respond well, or not at all.
Trial design stands to benefit from ‘responder analy-
sis’ [81–83] which enrols patients sequentially into a 
trial decision-tree; failing on one “arm” of the tree for 
whatever reason, e.g. intolerable side-effects or failure of 
analgesia enrols them into an alternative treatment arm. 
A similar approach was used in the design of the CATIE 
trial [84, 85] and there is now a literature on adaptive 
trial design [86–88]. This should come as no surprise 
given the preceding discussion. Assigning patients to 
treatments by their categorical diagnosis, rather than by 
signatures or prototypes leads to loss of valuable infor-
mation about individuals, and avoidable sample attri-
tion. The definition of aggregate, univariate outcomes to 
measure average treatment response of the group defined 
by their assumed categorical diagnosis further obscures 
clinically meaningful treatment response. To paraphrase 
Moore et  al. [80]—we should “expect [analgesic] failure 
but pursue success” by accommodating response profiles 
of individual patients rather than focusing on average 
(unimodal) response.
Multivariate trajectories preserve response information
To illustrate the impact of (1) preserving multidimen-
sional disease signatures and (2) considering multivariate 
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trajectories and outcomes, consistent with the two out-
lined themes, we present the following simulated exam-
ple of 100 patients and a hypothetical intervention which 
yields an 80% improvement for positive symptoms alone, 
but where only 50% of the patients respond. In assess-
ing treatment response, we are generally interested in 
changes in signs and symptoms, so we retain the exam-
ple of using the PANSS scale. However, changes in other 
relevant measures of disease states could also be used, 
for example, change in functional neuroimaging mark-
ers. If the usual approach of defining an aggregate, uni-
variate outcome is adopted, such as the sum of positive 
and negative PANSS scores, we arrive at the distributions 
in Fig. 2a. Note how at time 1 (prior to the intervention, 
light grey) there is a clear mode to the distribution. At 
time 2 (following the intervention) there is a wider vari-
ance in the summed score, but the average response does 
not differ significantly from time 1; in other words, this 
appears to be a failed trial. However, in Fig. 2b which pre-
serves the two-dimensional patient signatures in terms of 
positive and negative symptom load, there is a clear clus-
tering of signatures, highlighting a group of responders 
(light grey) from non-responders (black). Even in a sim-
ple two dimensional signature space, a dramatic effect is 
revealed which is otherwise overlooked using a univari-
ate measure of average response.
This simple demonstration illustrates the challenges 
faced by standard approaches to analysing treatment 
response based on linear (and generalised linear) models 
which by definition model a univariate random variable 
Y as the mean value of Y given the multiple predictors X 
[60]. If Y represents the ‘collapsed’ outcome—i.e. summed 
change in positive and negative scores or some dichot-
omised version of this, e.g.  >30% change—it is unsur-
prising that the different response profiles which are 
preserved and clearly visible in the multidimensional sig-
natures (Fig. 2b) are inaccessible and essentially lost from 
the analysis. The standard way of attempting to recover 
such effects is to use secondary outcomes, which in this 
case would be a change in the set of positive symptoms. 
The traditional treatment of secondary outcomes in the 
univariate framework is to correct for multiple compari-
sons to avoid type I errors (false positives). However, this 
correction may be more or less stringent, depending on 
the number of a priori hypothesised outcome variables, 
and ultimately one can never be certain that the outcome 
measures that survive in a particular analysis will be rep-
licated in different datasets or future trials. The advantage 
of addressing changes in individual symptoms within a 
multivariate disease trajectory framework is that rather 
than assigning different status to primary and second-
ary outcomes, and hence variable statistical fate follow-
ing correction, response is treated multi-dimensionally 
from the outset, so that individual symptoms are treated 
equally, as is their relation to their associated multidi-
mensional disease signature.
Operationalising trajectories
Without loss of generality we will restrict examples to two 
time points which can be taken to be before (time 1) and 
after the intervention (time 2). A signature represents a 
patient’s state at a given time, so a trajectory is a sequence 
of such signatures over time. A geometric interpretation 
of a single patient’s trajectory is the ‘line’ (a vector) in a 
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Fig. 2 a Univariate distribution of the aggregate summed total negative and positive symptoms at time 1 (before) and time 2 (after intervention) for 
a simulation of 100 patients where the intervention is effective in improving only the positive symptoms by around 80% in approximately 50% of 
patients. b PANSS positive and negative symptom scores in two-dimensions, with black dots showing patients who did not improve (non-respond-
ers), and light grey dots indicating those that did improve (responders)
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multidimensional space connecting at least two signa-
tures (as shown in Fig.  1a). This captures and describes 
change in a single patient, but provides no information 
about patterns, regularities or structure across many 
patients. Since there are potentially an infinite number of 
trajectories, it is necessary to find structure that enables 
inference over a tractable number, analogous to formally 
defining events and probability spaces—for discussion, 
see [89]. We have already shown how clusters can be 
learned, their prototypes defined and also, that signa-
tures can be hard- or soft-assigned to these clusters using 
simple metrics. We can therefore use the finite number 
of prototypes to assign patients to their nearest cluster at 
different time points. Trajectories are then modelled as 
a sequence of ‘movements’ (in multidimensional space) 
between different clusters at each time point.
Anticipating the experiments later in this paper, assume 
that at time 1, our collection of signatures supports a 
number of clusters for which we define prototypes—e.g. 
as the centroid of the cluster—and assign alphabetic class 
labels A, B, C and so on. Applying the procedure to the 
same patient signatures at time 2 (post-intervention) 
yields a different number and structure of clusters which, 
to distinguish from time 1, we label numerically as classes 
1, 2, 3 and so on. Note that these label assignments are 
purely categorical, and do not imply ordering, weight-
ing or ranking. The probability that a given patient is a 
member of each of the classes is a function of how simi-
lar the patient’s signature is to the corresponding proto-
types A, B, C at time 1. Using standard probability theory, 
a given patient’s trajectory is the likelihood of belonging 
to one of the classes (1, 2, 3) at time 2, given the prob-
ability that they belonged to each of the classes A, B, C, at 
time 1. Such a concept is captured naturally in the theory 
of Bayesian networks and graphical models [90] which 
in this example is simply the conditional probability of 
classes at time 2 on classes at time 1. This provides a trac-
table, countably-finite interpretation of trajectories that 
are supported by the data.
Trajectories and signature spaces allow flexibility 
in defining outcomes
Thus far, we have used the term trajectory to refer to 
movements in spaces of signatures representing response 
to an intervention and argued that this preserves valuable 
information (cf. Fig. 2a, b). We have intentionally avoided 
the term ‘outcome’ because this implies a univariate 
aggregate measure that is most often dichotomised to 
represent success or failure of treatment.
However, in our signature and trajectory model, 
response can acquire the meaning of an outcome once 
a set of conditions over the dimensions of the signature 
space is applied. For example, the bottom half of the 
space in Fig. 1b represents signatures where there is low 
positive, but variable negative symptom load. Therefore, 
an outcome in our model is specified as a region in the 
multidimensional signature space, whose semantics can 
be described as ‘clinically significant change in posi-
tive, but not necessarily negative symptoms’. This can be 
achieved by using the discriminant line (see Fig. 1b), such 
that any signature, or trajectory end point, that falls in the 
region below the discriminant line is deemed a treatment 
‘success’ in terms of specific change in positive, but not 
negative, symptom dimensions. Alternatively, the proto-
types for classes A and B can be used to define regions 
based on ‘soft’ assignment within a radius around each 
prototype, with class B similarly capturing the meaning 
of treatment success. There is a clear advantage to defin-
ing an outcome as a region demarcated by a discriminant 
line (or radius around a prototype) comprising essentially 
multiple thresholds within a multi-dimensional signature 
space, instead of applying one arbitrary threshold onto a 
univariate, aggregate measure, e.g. total PANSS score: by 
modelling high-dimensional trajectories which preserve 
useful information about change, and define what is clini-
cally meaningful multidimensionally, it becomes possible 
to account for heterogeneity in treatment response over 
individuals who respond in different ways, but respond 
nonetheless. In the context of a clinical trial, the inher-
ently richer, multidimensional specification of what 
constitutes response, or success, effectively reduces the 
possibility of a false negative result, which can result 
from defining success according to a single point on a 
collapsed univariate continuum as illustrated in Fig. 2.
Summary
1. Patients present with heterogeneous constellations 
of symptoms that do not respect disorder categories, 
even within a classical categorical diagnosis. This 
heterogeneity carries meaning and clinical utility. 
Recruitment into trials and interventions would be 
better defined as targeting dimensions of disorder 
signs and symptoms rather than categories of disor-
der. Variation and similarity between patients can be 
defined as multidimensional signature spaces.
2. The categorical assumption leads to defining out-
comes by collapsing multi-dimensional clinical state 
to univariate scalar or dichotomised variables. In 
doing so, information is lost in favour of simplicity 
of analysis in trials. By representing clinical states as 
multidimensional spaces of signatures, data driven 
techniques can identify prototypes that identify rel-
evant structure in these spaces. Trajectories defined 
as movement between classes and their prototypes at 
different times define how patients respond to inter-
ventions.
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3. Aggregate or ‘collapsed’ measures of clinical state 
and outcomes, as well as categorical disorder defini-
tion enable measurement of only the mean/average 
response to an intervention. Therefore, the reasons 
why an intervention works for some individuals but 
not others are obscured by solely examining average 
response for a group. By defining multidimensional 
signature spaces and utilising the prototypes therein, 
we preserve information and can flexibly define clini-
cally meaningful response by specifying conditions 
on multiple dimensions (i.e. by defining a region 
rather than a single threshold on a collapsed, univari-
ate aggregate measure).
Heterogeneity, stratification and trajectories 
of patients in the CATIE trial
To illustrate the potential of our multivariate framework 
we apply it to a real, large-scale naturalistic RCT of the 
efficacy of different antipsychotics. The CATIE trial [85] 
recruited patients on the basis of a categorical diagnosis 
of schizophrenia and assigned people to parallel arms 
for comparing the efficacy of a number of antipsychotic 
medications. If the originally assigned medication arm 
failed to treat the patient or side effects were intoler-
able, they were switched to another. For our experiments, 
following [91, 92] we extracted patient-level data with 
baseline PANSS scores as well as repeated neurocogni-
tive performance measures at baseline and at 2-month 
follow-up (although the CATIE protocol did not spec-
ify PANSS re-evaluation at 2  months). This yielded 750 
complete datasets. In Experiment 1, we use the baseline 
PANSS data to illustrate principles of multivariate sig-
natures (and prototypes) yielding structure that could 
be used for prospective patient stratification. In Experi-
ment 2, we apply our method to the neurocognitive data 
at times 1 and 2 to illustrate signatures, prototypes and 
trajectories.
Experiment one: patient heterogeneity and stratification
Our hypothesis is that there is heterogeneity and structure 
in the 750 CATIE patients which is overshadowed by the 
assumptions of a categorical diagnosis of schizophrenia. 
By comparing our multivariate framework to univariate 
measures of clinical state, we show that data-driven strat-
ification (e.g. a set of prototypes) is possible within this 
categorically defined group of patients.
Methods
The PANSS naturally forms a 30-dimensional space, 
with variates (items) measuring 7 positive, 7 negative 
and 16 general symptoms. First, the 750 patients were 
represented in the most reductive way, as one might to 
measure clinical state suitable for a univariate analysis, 
by forming the individual univariate distributions of total 
(summed) positive, negative and general symptoms. The 
multivariate approach to defining the signature space was 
then applied. As it is impossible to visualise a 30-dimen-
sional space, the total positive, negative and general 
scores were used to form bivariate (i.e. two-dimensional) 
representations of all patients, with signatures deter-
mined by combinations of positive and negative, positive 
and general and negative and general symptom scores, 
analogous to the approach in Fig.  2a, b. This represen-
tation preserves more information than the univariate 
approach, although there is still some loss of information 
as PANSS signatures form a 30-dimensional space.
Then, in the full 30-dimensional space of PANSS signa-
tures (which cannot be plotted), we perform data-driven 
unsupervised clustering using Rodriguez and Laio’s algo-
rithm [63] which finds clusters according to two criteria 
(using the same Euclidean metric discussed earlier) and 
has been shown to be robust across a number of low and 
high dimensional clustering problems. First, a quantity 
rho representing the local density for each patient’s signa-
ture is defined as the number of neighbouring signatures 
inside a specified radius. Then a quantity, delta, is defined 
for each signature as the minimum distance to any other 
signature with a higher local density rho. Prototypes are 
then identified as the individual signatures where delta 
is anomalously large, in other words, indicative of good 
separation from the nearest locally-dense clusters. We 
then assign each of the 750 patients to their nearest pro-
totype in 30-dimensional space, illustrating the signa-
ture-prototype structure by colour coding each patient by 
their cluster membership in the bivariate representation.
Results
Figure  3 (top row) shows the univariate (single dimen-
sional) representation for summed symptom domains 
(positive, negative and general). Each shows an approxi-
mately normal distribution but no clear heterogeneity 
beyond that captured by the mean/mode and variance.
The middle row of Fig.  3 shows bivariate plots of sig-
natures formed by combinations of symptom domains. 
Note how each combination of variables shows an 
approximately bivariate normal distribution, but where 
the centroid and covariance are quite different.
Applying the clustering algorithm [63] identified 8 
clusters in the full 30-dimensional space of PANSS sig-
natures. Figure 3 (bottom row) shows the bivariate plots 
from the middle row, but with each signature coloured 
according to the cluster assigned in the full 30-dimen-
sional space. It can be seen that univariate (Fig.  3, top) 
representations conceal heterogeneity that is visible in 
higher dimensional representations; as dimensionality of 
the representation increases, structure and heterogeneity 
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are revealed within the signature space. In contrast to the 
single univariate distribution, 8 clusters emerged in the 
30-dimensional space, representing an opportunity for 
stratification of patients by psychopathology.
Experiment two: trajectories in neurocognitive 
performance
Similarly to the PANSS signatures, our hypothesis is that 
there is heterogeneity and structure in patients’ neurocog-
nitive performance at baseline and follow up that can be 
exploited to define trajectories.
Methods
Neurocognitive performance in the CATIE trial was 
defined via Z-scores that summarise performance on 
cognitive tasks over five domains; verbal working mem-
ory, vigilance, speed of processing, reasoning, and mem-
ory [91, 92]. This forms a 5-dimensional signature space.
We proceeded as for Experiment 1; first, the univari-
ate distributions of each domain were computed sepa-
rately, then the 5-dimensional space was formed, which 
can be visualised using bivariate plots of combinations 
of cognitive domain performance (verbal  ×  vigilance, 
0.00
0.02
0.04
0.06
0 20 40 60
Total Positive
D
en
si
ty
0.00
0.02
0.04
0.06
0 20 40 60
Total Negative
D
en
si
ty
0.00
0.02
0.04
0.06
0 20 40 60
Total General
D
en
si
ty
0
20
40
60
0 20 40 60
Positive
N
eg
at
iv
e
0
20
40
60
0 20 40 60
Negative
G
en
er
al
0
20
40
60
0 20 40 60
General
P
os
iti
ve
0
20
40
60
0 20 40 60
Positive
N
eg
at
iv
e
0
20
40
60
0 20 40 60
Negative
G
en
er
al
0
20
40
60
0 20 40 60
General
P
os
iti
ve
Fig. 3 Baseline PANSS scores from the CATIE data set for 750 participants from [91, 92]. Top Panel distributions of univariate total positive, negative 
and general symptom scores across all patients. Middle Panel bivariate (2D) spaces of signatures obtained when each patient is represented by their 
positive × negative, negative × general and general × positive symptoms. Lower Panel the plots from the middle panel, but with each patient 
signature coloured according to the cluster assigned using data-driven clustering in the original 30-dimensional space—8 clusters were discovered 
in total. Data points in all plots are jittered for ease of visualisation
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verbal  ×  speed, vigilance  ×  speed, vigilance  ×  reason-
ing and so on). Prototypes were derived by applying the 
clustering algorithm in the 5-dimensional space, assign-
ing each patient to the nearest cluster by distance to pro-
totype, and finally, colour coding patients in the bivariate 
plots according to the assigned cluster. To illustrate tra-
jectories, we apply the clustering algorithm separately at 
baseline (time 1) and two-month follow up (time 2). To 
show how trajectories can be formalised probabilisti-
cally, we then compute the probabilities of belonging to 
each cluster at time 2, given the probability of this patient 
being in each cluster at time 1; a simple discrete Bayes-
ian network was modelled using the gRain package [93]. 
We then illustrate how a ‘test’ patient’s trajectory can be 
found by first computing the patient’s distance to proto-
types at time 1. Then, we compute the conditional prob-
abilities of cluster membership at time 2 given their 
original cluster.
Results
As the number of bivariate combinations of each of the 5 
cognitive domains is large (requiring 10 separate plots), 
in Fig. 4, we display verbal working memory as an exam-
ple known to be impaired in patients with schizophrenia 
and first-degree relatives [94]. Following the approach 
in Experiment 1, the univariate plot of verbal working 
memory and corresponding bivariate plots by vigilance, 
processing speed, reasoning and memory are shown. 
The top row shows time 1 (baseline) and the bottom row 
time 2 (follow-up at 2 months of treatment). If a univari-
ate measure alone is defined for verbal working memory 
(column A) and scores at time 1 and 2 (top, bottom row) 
are directly compared, there is little discernible change.
The top row of Fig. 4b–e reveals 3 clusters within the 
patient group at time 1 supported by the data in the 
5-dimensional space. Note that these are not completely 
contained in any part of the two dimensional representa-
tions, illustrating how information is lost as dimension-
ality is reduced. At time 2 (Fig.  4, bottom row, panels 
b–e) application of the algorithm separately on this space 
revealed 5 clusters, suggesting a higher degree of hetero-
geneity after treatment. In other words, patient trajecto-
ries can be described as ‘starting’ in one of 3 clusters and 
diverging to ‘arrive’ into one of a separate set of 5 clusters 
after treatment.
To quantify trajectories over the entire cohort of 
750 patients, we computed for each patient the condi-
tional probability of belonging to each of the five clus-
ters at time 2, given the probability that the patient was 
in one of the three clusters at time 1. In Fig. 5, we label 
the three clusters at time 1 as a, b and c to emphasise 
that they are different to the clusters obtained at time 2 
which are labelled numerically, 1–5. Figure 5a shows the 
overarching structure of trajectories for all 750 patients 
between clusters at time 1 and time 2. The line weight is 
proportional to the probabilities of ‘arriving’ in clusters 1 
through 5 at two month follow-up, given the probability 
of starting at baseline in clusters A, B or C (Fig. 5b).
Fig. 4 Trajectories in the CATIE neurocognitive measures with baseline and signatures prior to intervention (Top Row) and at 2 months after ran-
domisation and intervention (Bottom Row). a Univariate distribution of verbal memory; b–e Bivariate plots of each combination of verbal memory 
against vigilance, processing speed, reasoning and working memory respectively. At Time 1, unsupervised clustering reveals 3 clusters (one is very 
small and not clearly visible) for the group. At Time 2, there are 5 clusters supported by the data
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The same model can be used to predict a patient’s 
trajectory which is crucial to the idea of stratifica-
tion solely on the basis of their signature at time 1. 
Figure  5c shows the location of a ‘case’ patient (black 
circle), in relation to cluster A, B and C prototypes at 
time 1. Figure 5d displays the likelihood at time 1 of this 
test patient belonging to clusters A, B or C as a prob-
ability distribution, representing ‘soft’ assignment and 
stratification. By querying the Bayesian network model 
with these likelihoods [95, 96], it is possible to extract 
the conditional probabilities of arriving in any of the 5 
clusters at time 2. For this patient, Fig. 5f contains these 
corresponding predictions: clusters 2 and then 4 are the 
most likely ‘end points’ of the trajectory for this patient. 
The actual end point of this patient’s trajectory is close 
to the prototypes for the most-likely predicted clusters 2 
and 4 (Fig. 5e).
Systematic review of trials for neurocognitive 
symptoms of schizophrenia
To demonstrate the scope of our proposal and how it 
might influence trial design, we conducted a system-
atic review of the Clinical Trials registry to locate trials 
on cognition in schizophrenia over the period 1st Janu-
ary 2004 through 1st September 2015. The aim of this 
review was not to assess the quality of trials as reported, 
for example whether significant effects were obtained 
or whether these were adequately powered. Instead, we 
sought to systematically interrogate the extent to which 
they are characterised by assumptions of categorical and 
univariate assumptions relating to diagnosis and out-
come, which as we have argued are incongruent with a 
stratified psychiatry. Using the set of criteria outlined 
below, which were designed in line with our proposed 
stratification framework, we sought to assess broadly the 
extent to which this recent body of work actually mirrors, 
conceptually and methodologically, the growing consen-
sus for the need to stratify.
Method and data extraction
Registered trials recruit for one or more categorical 
diagnoses, therefore, these definitions were necessar-
ily used to mine the literature. Using the Clinical Trials 
registry (https://clinicaltrials.gov/), our search terms 
were as follows: trials registered between 01/01/2004 and 
01/09/2015 limited to conditions defined as “schizophre-
nia” AND (“cognition” OR “cognitive”). Interventions 
were kept broad, and included trials with titles including 
“drugs” OR “behavioural” OR “dietary” OR “device” OR 
“transcranial” OR “fMRI” OR “cognitive” in order to cap-
ture the largest range of interventions. Primary or sec-
ondary outcome measures were included.
Our initial search yielded 114 trials that met the screen-
ing criteria. We then excluded 89 records where results 
were not accessible or were unreported. Of the remain-
ing 25 registered trials, 2 further studies were excluded 
because there was no reporting of primary or secondary 
outcomes that included measures specific to cognition 
(see Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) diagram in Fig. 6) suggest-
ing less relevance.
The design and reported analyses of the remaining 23 
studies were examined. For each trial, the full text and 
results tables were examined by two authors (DWJ and 
JP). For 8/23 trials, results had also been published in 
journals and these articles were reviewed and tabulated 
alongside information from the trials database.
Each trial was assessed according to the following 
criteria:
1. Diagnostic categories (e.g. schizophrenia, schizoaffec-
tive) and the criteria used, which, for all studies, was 
either DSM-IV, DSM-IV-TR or not specified.
2. Within the diagnostic inclusion criteria, which spe-
cific symptoms/features (for example, as used in the 
research domain operational criteria), domains (e.g. 
positive or negative symptoms) or smaller groups of 
symptoms were specified as inclusion/exclusion crite-
ria. This represented recognition of the heterogeneity 
of the categorically labelled disorder.
3. Which patient-specific variables were included in the 
design—for example, whether symptom signatures/
profiles measured by a specific instrument scale/sub-
scale were considered along with endophenotypes or 
biomarkers such as genomic data, functional mag-
netic resonance imaging (fMRI), electroencephalog-
raphy (EEG) features, hypothesised as mediators of 
response.
4. Primary and secondary outcomes and their respective 
measurement type: if composite/aggregate measures 
where used such as total or mean scores, or domain 
specific scores on specific subscales/instruments. 
For example, if a cognitive battery such as Measure-
ment and Treatment Research to Improve Cognition 
in Schizophrenia (MATRICS) or Brief Assessment of 
Cognition in Schizophrenia (BACS) was used as pri-
mary outcome, were individual sub-tests measured 
and reported, or only the composite “overall” score. 
The measure of change was also examined in terms 
of hours, days, weeks, months or years and whether 
statistically significant results were reported.
5. Whether the primary and secondary outcomes 
where tested relative to patient-specific variables—
for example, change on immediate recall tests with 
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respect to a given biomarker or accounting for symp-
tom signatures or responder status.
Trials accumulated points depending on the quality 
of specification of the aforementioned criteria, so that a 
score was assigned for the following:
1. If the study included specific symptoms or groups of 
these (Criterion 2) or patient specific variables (Cri-
terion 3), it scored 1 point. If the study included both 
Criteria 2 and 3, it scored 2 points.
2. If the study considered primary or secondary out-
comes and change measures, where it would be pos-
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Fig. 5 a Trajectories represented as a graph with nodes shown for clusters A, B and C at baseline (time 1) and clusters 1–5 at follow-up (time 2); 
heavier line weights between clusters denote higher probability of transitioning to each cluster at time 2, given the patient was in one of clusters 
A, B or C at time 1 b Table of probabilities corresponding to line weights in a. c Bivariate plot (Time 1) reproduced from Column B of Fig. 4. Baseline 
patient signatures at time 1, with diamonds showing approximate projected location of prototypes of clusters; a single ‘case’ patient signature is 
represented by a black dot. d The probability distribution of the ‘case’ patient belonging to clusters A, B or C (in 5 dimensional space—note that 
projecting into 2 dimensions results in distortion which visually misrepresents the nearest prototype). e At time 2, the ‘case’ patient’s signature dem-
onstrates a trajectory of improvement in both verbal memory and vigilance performance. f Probability distribution of the ‘case’ patient’s member-
ship to the clusters at time 2 given (conditional on) the probability the test patient was in cluster B at time 1
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sible to explore individual response, trajectories and 
differences (e.g. if domain specific subscales rather 
than only composite/total scores—see Criterion 4) 
the study scored a further 2 points. If only total or 
composite scores were reported, only a single point 
was scored.
3. A further 1 point was scored for Criterion 5, where 
outcomes were analysed accounting for specified 
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Fig. 6 PRISMA Diagram for review of clinicaltrials.gov database
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subject-specific variables. For example, if an attempt 
was made to address individual patient-level factors 
in mediating response or change in an outcome.
The range of scores was therefore 0–5. If there was 
insufficient reported information (either in the tri-
als database, or in accompanying published articles), 
the above rubric was conservatively applied favouring a 
lower score. If the design of the study recorded an inten-
tion to explore features described in the criteria (e.g. to 
explore genetic predictors, subgroups in psychotic disor-
ders), but it was not mentioned further (e.g. in reported 
results) then the rubric was applied generously, favouring 
the higher score. This allowed for studies that were com-
pleted and closed, but where all results had not been ana-
lysed and published on clinicaltrials.gov.
As an example, if a study recruited subjects with schiz-
ophrenia or schizoaffective disorder with specific posi-
tive features and cognitive symptoms (such as thought 
disorder and impaired verbal working memory), with a 
hypothesised biomarker such as regional fMRI activity 
change in then by Criteria 2 and 3, 2 points were scored. 
If the same study records the a specific medication as the 
intervention, with primary outcome being change in the 
biomarker and individual symptom domains, then by 
Criterion 4, a further 2 points are accumulated. If second-
ary outcomes were changes in specific symptom profiles 
(e.g. thought disorder) mediated or grouped by the study 
biomarker, a further point would be scored by Criterion 
5, resulting in a total score of 5. This would describe a 
study where the proposals of this paper are accounted for 
or there is potential to re-analyse the data using the same 
principles. Lower scores indicated that the studies were 
more vulnerable to the problems described in the themes 
articulated in this paper.
Results
Table 1 shows the complete set of 23 included trials. Of 
these, 19 were efficacy or augmentation trials, most with 
a novel application of a drug: 13 of these were repur-
posing trials, where a drug with an existing license for a 
different indication was trialled for cognition in schizo-
phrenia, 5 tested new compounds and 1 was an exten-
sion study from adult to a paediatric indication. In total, 
7 of the included trials have been published (citations are 
given in Table 1).
Scoring
By applying the scoring criteria to the 18 studies 1 study 
NCT00611806 [97] scored 5, the highest score, indicat-
ing highest compatibility with the criteria; 5 studies 
scored 4 indicating high compliance and the potential to 
use the methods proposed in this paper; 2 studies scored 
3 indicating that the trial would be difficult to translate 
in our proposed framework. Scores of 2 and 1, indicat-
ing poor compatibility were achieved by 9 and 1 stud-
ies respectively, that is, half of the total reviewed (see 
Table 1).
We consider that those trials scoring 4 (NCT00548327, 
NCT00963924, NCT00435370, NCT00506077, NCT004 
55702) could be used in the framework we describe by 
reanalysis of the data.
Those scoring 3 or less would require substantial revi-
sion of design to use the framework proposed here, either 
because of design or data recording issues such as not 
including specific symptoms, or the use of only compos-
ite scores to measure patient signatures.
Of note, of the 6 trials scoring 4 or 5, five were pub-
lished studies, suggesting that peer review processes are 
sensitive to and aligned with the principles discussed in 
this paper.
Factors affecting response
Of the 18 studies, 10 studies considered specific disorder 
features; of these, 6 defined the features using “thresh-
old” definitions—e.g. cognitive impairment or PANSS 
exceeding a value—and the remainder used qualitative 
descriptors such as “acute exacerbation” and “depressive 
subtype”. Ten studies defined individual-specific descrip-
tors which might predict or mediate response; three of 
these studies used biomarkers (EEG, fMRI or genom-
ics)—the others defined clinical state measures (e.g. neg-
ative symptoms, clinically stable on named antipsychotic, 
illness duration and cognitive performance). Four studies 
both defined patient-specific descriptors and analysed 
the primary outcome with respect to these. Only one 
study considered all of these factors NCT00611806 [97].
Response/outcome measurement
For primary outcomes defined on clinical state (e.g. by 
PANSS scales), 4/18 studies considered domain scores—
for example where individual components or subscales 
were used instead of mean, total or composite scores. 
Perhaps unsurprisingly, secondary outcomes reflected 
more attempts to understand multi-dimensional (rather 
than univariate) measurement of clinical state change: 10 
studies included “domain scores” or some subscale-based 
test of the hypotheses, but only three actually analysed 
how the stated patient-specific factors would impact on 
the domains.
Discussion and conclusions
In this paper, we have described how relying on cat-
egorical disorder definition leads to untenable assump-
tions about homogeneity in patient populations, impacts 
on the assessment of treatment and finally, coerces 
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measurement of outcome to group averages sacrificing 
valuable response heterogeneity. We have shown how to 
operationalise proposals from the literature on dimen-
sional definition of disorders consistent with proposals 
such as RDoC. To this end, we have introduced concepts 
of signatures, prototypes and trajectories, and operation-
alised these from first-principles using concepts from 
multivariate statistics, pattern recognition and proba-
bilistic reasoning. Using well established data from the 
CATIE trial as an example, we have shown it is possible 
to apply these concepts for stratification, to define multi-
dimensional trajectories and derive outcomes.
By systematically reviewing just over a decade of clini-
cal trials registry data, we show that a majority of studies 
are contaminated or confounded by assumptions that are 
misaligned with principles of stratified psychiatry. This 
could explain the limited success in finding interventions 
that work for patients in the domain of neurocognitive 
symptoms in psychosis, which have been identified to be 
significant predictors of quality of life and functional out-
come. Only a third of the studies reviewed scored 4 or 5 
on our criteria, suggesting compatibility with the princi-
ples outlined in our proposal. We now consider specific 
implications of our proposal, highlighting limitations and 
future research directions.
Clinical symptomatology and neurocognitive data have 
been used throughout as examples in aid of developing 
our arguments, primarily to emphasise commonality 
between clinical diagnoses, outcomes and stratification. 
Our approach generalises to other kinds of data such as 
neuroimaging and genomics (“Dimensional definitions 
of disorder” and “Learning models of signatures” sec-
tions), as both symptomatology and biomarker data are 
amenable to such treatments and similarly subject to 
constraints arising from data complexity arguments that 
exceed the scope of this paper. While these are not triv-
ial problems, they are now tractable with contemporary 
computational resources and recent advances in algo-
rithm design. Genomics research [98, 99] has seen the 
application of pattern classification and regression tech-
niques more generally [100, 101], with debate focusing 
on feature selection [102, 103], sparse sampling [57], the 
‘curse’ of dimensionality [104] and asymptotic classifica-
tion performance as the dimensionality of data increases 
[105].
Implications for patient recruitment and stratified trials
We now consider the practical application of our propos-
als for trial design. The first and most obvious implica-
tion is to recruit patients for constellations of symptoms/
signs in alignment with candidate biological mechanisms 
from the RDoC. As our systematic review demonstrates, 
almost all trials recruit for a diagnosis in expectation of 
a response that follows a unimodal average for the diag-
nostic group but few explore or even define outcome in 
terms of features of the illness.
Traditionally, if the aim is to study and treat disorgani-
sation in psychosis [106, 107], a disorder (schizophre-
nia) and a cut-off measure over some constellation of 
symptoms (e.g. threshold over an aggregate of PANSS or 
SANS scores) might be defined, in the face of the known 
difficulties in robustly defining presumed syndrome or 
subtype of schizophrenia [108] or neurocognitive cor-
relates [109]. Alternatively, in our framework, we would 
accept patients who display signs and symptoms clini-
cally consistent with disorganisation syndrome regard-
less of a diagnosis of schizophrenia or schizoaffective 
disorder for instance. Similarly, in re-examining exist-
ing trial data or using N-of-1 trial databases, we would 
ignore categorical diagnosis. Next, each patient’s signa-
ture is defined by their neurocognitive performance and 
signs/symptoms profile (e.g. PANSS). Prototypes can be 
defined (1) according to clinical judgement (on group-
ings of patients’ signatures that clinicians agree are the 
most representative) or (2) using data-driven approaches 
(e.g. Experiment One). In both cases, visualisation and 
exploration of multidimensional signatures is required. 
Then, a ‘radius’ around these prototypes defines how 
any individual is ‘typical’ of, or similar to, the proto-
types, enabling continuous inclusion based on distance 
from the prototype or if one requires ‘hard’ inclusion/
exclusion, discriminant rules can be defined on the basis 
of prototypes. More patients can be included but each 
patient is assigned a ‘weight’ of class membership (with 
classes being defined by prototypes or discriminant sur-
faces); increasing study power, but at the potential risk 
of treatment exposure. Alternatively as in [3], one could 
data-mine existing populations of patients with schizo-
phreniform illness for appropriate candidate prototypes, 
mirroring Experiment One.
The same approach applies to parallel-arm or switch-
over designs [81, 82], including naturalistic designs such 
as CATIE. Assume we wish to compare the effective-
ness of two treatments, and hypothesise that there may 
be benefit for patients with a disorganised syndrome and 
less so for patients with pronounced positive symptoms. 
We define a treatment arm for patients with a disorgan-
ised syndrome whose prototype is distinct from those 
with more pronounced positive symptoms. Patients can 
then be assigned based on similarity to prototypes for the 
treatment arms, or randomly; but their multidimensional 
signature is retained.
Second, we turn to trajectories. In contrast to tra-
ditionally defined univariate aggregate outcomes, the 
multidimensional approach necessitates specification of 
changes along each axis of the signature space to define 
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outcomes a priori, e.g. for pre-trial registration. Signa-
ture spaces can be parcellated by discriminant surfaces 
or by ‘soft’ membership to clusters that divide the space 
into regions. These regions can be learned from pre-
existing data, or specified a priori. Treatment response 
is embodied in a trajectory where the pre-treatment sig-
nature moves to a location after treatment that lies in 
some pre-specified region—i.e. one ‘side’ of a discrimi-
nant surface or within a radius of a prototype. Defining 
improvement over the constellation of disorganisation 
signs and symptoms will result in a region that is distinct 
from improvement in positive symptoms (which is lost 
if aggregate univariate outcomes are used). If assign-
ment to treatment arms is random, treatment effective-
ness can be crudely estimated as the number of patients 
who, after treatment, transitioned to each region given 
their similarity to their pre-treatment prototypes after 
treatment.
In terms of stratifying patients prospectively, recent 
proposals [110] consider using individual patients as N-
of-1 trials, thereby rendering routine clinical practice a 
source of data to maximise data availability and a basis 
for making inferences. N-of-1 trials require formalisa-
tion of data collection in routine clinical practice and our 
framework is compatible with collecting and measuring 
response in a format useful for prospective stratification. 
A candidate patient case can be assigned to interventions 
based on prototypes acquired from historical informa-
tion. As above, similarity to the prototype of interest (a 
cluster discovered in previous cases) is propagated for-
ward into the analysis of trajectory and response. If two 
patients respond similarly, that is, their signatures after 
intervention are similar, but a third patient does not as 
their signature lies at a greater distance from the other 
two, then the respective signature distances preceding 
the intervention may represent a meaningful explanatory 
covariate in parsing why the third patient did not bene-
fit; or indeed, predicting that another patient, at a simi-
lar distance to the third patient, will not respond to the 
intervention.
This model is not only useful for data with inherent 
heterogeneity. Even when the space of patient signatures 
suggests only a single group, recruitment and stratifica-
tion is no worse off than when recruiting for categorical 
disorder. However, signatures and trajectories naturally 
translate into region-based outcomes which as discussed, 
render trials less prone to false negatives due to the flexi-
bility afforded by their multidimensional definition. Thus, 
even within a relatively homogenous group of patients, 
trajectories offer a rich source of information on those 
who benefitted and the extent to which they did so.
Implications for the nosology of psychiatric disorders
We have argued that recruiting individuals for a categori-
cal diagnosis leads to incorrect assumptions about meas-
uring how they respond to treatment. Primarily, we have 
proposed methods for stratifying patients, rather than 
redefining categories of disorder, just as RDoC empha-
sises disease signatures underwritten by biological pro-
cesses. Specifically, [3] describes how a large collection 
of people with different a priori categorical disorders are 
aggregated together because of shared disease features; 
for example, major depressive disorder, dysthymia (mild 
depressive disorder) and depressive-phase bipolar disor-
der all share affective symptoms and signs. Then, large 
collections of endophenotype and biomarker data for this 
population are used to derive data-driven clusters for dis-
order classification (i.e. exposing common and distinct 
biological processes underpinning signs and symptoms).
Implications for analysis of trials
We have argued that simple aggregation and dichoto-
misation of a multidimensional measure of clinical state 
(e.g. after a trial intervention) to a univariate scalar out-
come discards and obscures relationships that may 
exist in the original multidimensional representation of 
clinical state as would any data dimensionality-reducing 
method [111]. Yet this represents a costly trade-off for 
ease of analysis and compatibility with established and 
well-understood statistical techniques; one is forced to 
derive a univariate outcome in order to utilise multi-
variable regression techniques which map multiple inde-
pendent/predictor variables to a univariate dependent 
variable/outcome. The unfortunate cost of this conveni-
ence is loss of information in terms of statistical rela-
tionships present in the higher-fidelity multidimensional 
representation. Our framework is aligned with the RDoC 
and proposes refocusing on disorder features, signs and 
symptoms. We have made a case for ‘quantising’ these 
high-dimensional spaces by learning prototypes that rep-
resent data-driven locations in the space of patient sig-
natures that provide meaningful structure. This converts 
high-dimensional signature spaces into a tractable num-
ber of locations such that trajectories can be defined as 
events to be modelled using probability theory and statis-
tics. While we discussed learning or estimating models of 
prototypes and trajectories using a statistical interpreta-
tion, our proposal can also be viewed within non-prob-
abilistic frameworks such as high-dimensional function 
approximation or within the broader framework of mani-
fold theory [112, 113].
Future work is needed to expand on how uncertainty 
in outcomes can be represented in our framework. In 
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frequentist and Bayesian statistics, effect sizes on out-
comes have confidence and credible intervals respec-
tively. While there is no theoretical obstacle, evidence 
derived from trials usually hinges on dichotomised out-
comes for ease of implementation, e.g. as treatment pro-
tocols. It is likely that consulting tables of statistically 
significant regression coefficients for a single outcome 
will not suffice, and benefit instead from the implementa-
tion of evidential reasoning algorithms such as Bayesian 
networks in Experiment 2.
Inference for discovery versus prediction
Whether used for predicting outcome or diagnosis, any 
statistical method including machine learning, multivari-
ate statistics or the more familiar generalised linear mod-
els, is vulnerable to difficulties replicating results or model 
selection and validation on independent samples and this 
has hampered current research. For example, in the con-
text of gene hunting, searching for neuroimaging mark-
ers of disease, or investigating the success or failure of an 
intervention, we seek an answer to one or more hypoth-
eses while simultaneously, bolstering support for strong 
association or causality by controlling for confounds 
within the experimental design. The definition of validity 
in explanatory modelling [114] is therefore the discrep-
ancy between the model’s prediction output with respect 
to the data it was fitted to. In this approach, hypotheses 
are tested (i.e. that the estimated regression coefficients 
on predictor variables are non-zero) with no explicit 
requirement that they generalise beyond the study data. 
Instead, replication and validation of findings proceeds by 
repeating the experiment (or trial), fitting similar models 
and retrospective comparison with the previous studies.
We contrast this to inference for prediction [114] and 
stratification where we are less concerned with discovery 
(explanation), and focus instead on how available infor-
mation can be used to prospectively optimise treatment 
for the individual. In this case, the ‘gold standard’ for 
model validity is not its fit to collected data, but rather, 
how well the model predicts in the case of novel inde-
pendent data sets. Our proposal thus comes with a health 
warning: inferences drawn from analyses such as those 
presented above using the CATIE trial data should not 
be used to retrospectively assert causality as inference 
for discovery. Instead, we should couch stratification 
and prediction in terms of probabilistic assignments of 
‘weight’ given available information: e.g. “this patient has 
a 0.75 probability of a positive outcome on positive symp-
toms given treatment 1, and 0.60 with treatment 2 given 
they were close to prototype A, but not B”—see [115] 
for examples of similar reasoning with clinical exam-
ples. We propose that techniques suited to this task are 
likely to resemble efforts in the probabilistic reasoning 
community, such as graphical models that enable statisti-
cal structure in multivariate data to be discovered, mod-
elled and then used for prediction [90, 96].
Methodological challenges: model validation 
and replication
We have argued that multivariate signatures represent 
the fundamental ‘unit’ for describing patients and that 
assessment or measure of outcome in the form of tra-
jectories should respect this. To evaluate the efficacy of 
such a stratified psychiatry, any predictive model should 
be validated by its’ ability to predict on independent sam-
ples (cf. explanatory models) and this has been lacking 
in over three decades of published studies (see [116] for 
a review). Validation on truly independent samples is 
challenging because patient-level data is either not suit-
ably collected, or made available; of the existing studies 
similar to our proposed framework (reviewed in “Learn-
ing models of signatures” section), only two [64, 71] 
make use of independent samples and all rely on cross-
validation for model validation and selection to mitigate 
against over-optimistic results due to over-fitting e.g. 
the bias-variance trade-off [57] and inductive bias [117]. 
Model validation is beyond the scope of this paper, but 
is addressed in the literature on model selection more 
generally [118] and criteria for accepting any model 
(acquired by any statistical method) can be approached 
from a frequentist, information theoretic or Bayesian 
perspective [119]. The choice of criteria varies depending 
on the intended use of the algorithm and the definition of 
‘associational’ versus ‘causal’ [120, 121].
As we have demonstrated in the systematic review, 
data collected using existing clinical trial methods rarely 
align with the proposals we describe, or those of others [3, 
110]. To partially mitigate against this problem, the field 
is currently constrained to within sample cross-validation 
[122, 123], whereby one part of a dataset is used to build a 
model, while the remainder is used for testing its predic-
tive performance. Moreover, given small sample sizes of 
expensive biomarker data (e.g. neuroimaging and ‘omics’ 
data), cross-validation is performed with recourse to its 
logical extreme (leave-one-out, LOOCV), but replica-
tion failure is unfortunately predictable given that these 
subsamples are not truly independent. Robust validation 
requires testing against novel large datasets with adequate 
resolution in patient level data and compatible measures, 
conserved across multiple time points; in other words, 
organised with stratification and prediction in mind from 
the outset. There are, to our knowledge, no such reposi-
tories for psychiatric research. A particularly useful pro-
posal [124] is to build repositories of not only data, but 
trained models which can be applied to other data sets. 
This requires standardisation and interfaces that allow 
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exchange of data and implementations of algorithms in a 
common format. In this way, stratified psychiatry, and our 
proposal which speaks to it, can progress from the explor-
atory phase to validation and prospective testing.
Conclusion
 We have presented a concrete proposal in response to 
the growing calls and clear need for the realisation of a 
truly stratified psychiatry. Our approach meets this need 
by integrating principles and methods from the mature 
fields of multivariate statistics and probabilistic reasoning 
with an evolving nosology in psychiatry. We have drawn 
on schizophrenia as a particularly challenging and per-
tinent field of research and clinical practice where treat-
ment resistant disease continues to plague the lives of 
patients and defy scientists to the extent that it is often 
considered a separate clinical entity. The thorny problem 
of treatment resistance may be rendered more tractable 
if it is addressed in the context of movement in multidi-
mensional signature spaces. By preserving and exploiting 
heterogeneity and embracing the principles of stratified 
psychiatry, our work can begin to productively focus on 
defining trajectories for subgroups of individuals with 
quantifiably similar signatures.
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